BioInvent International AB (publ) (BOVNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioInvent International AB (publ) (BOVNF) with AI Score 51/100 (Hold). BioInvent International AB is a clinical-stage biotechnology company based in Sweden. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026BioInvent International AB (publ) (BOVNF) Healthcare & Pipeline Overview
BioInvent International AB, a Swedish clinical-stage biotech firm, specializes in immuno-modulatory antibodies for cancer. Its lead candidate, BI-1206, targets non-Hodgkin lymphoma and solid tumors, supported by strategic collaborations with Pfizer and Merck. The company operates in a competitive landscape, focusing on novel cancer therapies.
Investment Thesis
BioInvent International AB presents a compelling investment case based on its innovative immuno-oncology pipeline and strategic collaborations. The lead drug candidate, BI-1206, holds significant potential in the treatment of non-Hodgkin lymphoma and solid tumors, with ongoing clinical trials providing key data points. The collaborations with Pfizer and Merck validate the company's technology and provide financial support for development programs. With a market capitalization of $0.22 billion, BioInvent offers exposure to the high-growth immuno-oncology market. Upcoming clinical trial results for BI-1206 and other pipeline assets represent potential catalysts for value appreciation. However, the company's negative P/E ratio of -4.51 and negative profit margin of -147.0% highlight the risks associated with clinical-stage biotechnology companies, including the uncertainty of regulatory approvals and the need for additional funding.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead drug candidate BI-1206 is in clinical development for non-Hodgkin lymphoma and solid tumors, representing a significant potential revenue stream.
- Strategic collaboration with Pfizer Inc. to develop antibodies against tumor-associated myeloid cells, providing financial and scientific validation.
- Partnership with Transgene to co-develop multi-functional oncolytic viruses for solid tumor treatment, expanding the company's therapeutic modalities.
- Collaboration and supply agreement with Merck for clinical development of BI-1808, enhancing the drug's development and market reach.
- Gross margin of 98.5% indicates strong potential profitability upon successful commercialization of its drug candidates.
Competitors & Peers
Strengths
- Innovative immuno-oncology pipeline with novel drug candidates.
- Strategic collaborations with major pharmaceutical companies.
- Strong intellectual property portfolio.
- Experienced management team with expertise in drug development.
Weaknesses
- Limited financial resources as a clinical-stage company.
- Dependence on partnerships for late-stage development and commercialization.
- High risk of clinical trial failures.
- Negative profitability and reliance on external funding.
Catalysts
- Upcoming: Clinical trial results for BI-1206 in non-Hodgkin lymphoma and solid tumors.
- Upcoming: Progress in the development of anti-TNFR2 antibodies BI-1808 and BI-1910.
- Ongoing: Expansion of strategic collaborations and partnerships with pharmaceutical companies.
- Ongoing: Advancement of novel immuno-oncology assets through preclinical and clinical development.
- Ongoing: Potential for regulatory approvals and commercialization of drug candidates.
Risks
- Potential: Clinical trial failures and setbacks in drug development.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Potential: Regulatory hurdles and delays in drug approval.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: Economic downturn and reduced healthcare spending.
Growth Opportunities
- Expansion of BI-1206 Clinical Trials: BioInvent has the opportunity to expand the clinical trials for BI-1206 to include additional cancer types and patient populations. This could significantly increase the potential market for the drug, which is currently focused on non-Hodgkin lymphoma and solid tumors. The global market for lymphoma treatment is projected to reach $17.9 billion by 2027, presenting a substantial opportunity for BioInvent. Success in these expanded trials could lead to accelerated regulatory approval and commercialization.
- Advancement of Anti-TNFR2 Antibodies: The development of BI-1808 and BI-1910, anti-TNFR2 antibodies, represents another significant growth opportunity. These antibodies target solid tumors and cutaneous T-cell lymphoma, addressing a market with substantial unmet needs. The global market for T-cell lymphoma treatment is expected to grow to $2.5 billion by 2028. Positive clinical trial results for these antibodies could lead to valuable partnerships and licensing agreements.
- Strategic Collaborations and Partnerships: BioInvent can leverage its expertise in immuno-oncology to establish additional strategic collaborations and partnerships with pharmaceutical companies. These collaborations can provide financial resources, access to new technologies, and expanded market reach. The company's existing partnerships with Pfizer and Merck demonstrate its ability to attract and maintain valuable relationships within the industry. Pursuing further collaborations will be crucial for long-term growth and success.
- Expansion into New Geographic Markets: BioInvent has the opportunity to expand its operations into new geographic markets, particularly in Asia and Latin America. These regions offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer. Establishing a presence in these markets would require strategic partnerships and investments in local infrastructure, but could significantly increase the company's revenue and market share.
- Development of Novel Immuno-Oncology Assets: BioInvent can continue to invest in research and development to expand its pipeline of novel immuno-oncology assets. This includes exploring new targets and mechanisms of action, as well as developing innovative drug delivery systems. By staying at the forefront of scientific innovation, BioInvent can maintain a competitive advantage and capitalize on emerging opportunities in the immuno-oncology market. The company's focus on tumor-associated myeloid cells and cancer-associated regulatory T cells positions it well to develop groundbreaking therapies.
Opportunities
- Expansion of clinical trials to new cancer types and patient populations.
- Advancement of anti-TNFR2 antibodies for solid tumors and cutaneous T-cell lymphoma.
- Establishment of new strategic collaborations and partnerships.
- Expansion into new geographic markets.
Threats
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Uncertainty of clinical trial outcomes.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary immuno-modulatory antibody technology platform.
- Strong intellectual property portfolio protecting its drug candidates.
- Strategic collaborations with major pharmaceutical companies like Pfizer and Merck.
- Expertise in targeting the tumor microenvironment and modulating the immune system.
About BOVNF
BioInvent International AB (publ) was founded in 1996 and is headquartered in Lund, Sweden. The company operates as a clinical-stage biotechnology firm dedicated to the discovery and development of novel immuno-modulatory antibodies for cancer therapy. BioInvent's primary focus is on addressing unmet needs in the treatment of various cancers through innovative research and development. Their lead drug candidate, BI-1206, is currently in clinical development for the treatment of non-Hodgkin lymphoma and solid tumors. This antibody is designed to target and modulate the tumor microenvironment, enhancing the body's immune response against cancer cells. Beyond BI-1206, BioInvent is also developing a portfolio of other immuno-oncology assets, including antibodies targeting tumor-associated myeloid cells, cancer-associated regulatory T cells, BT-001 in solid tumors, and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. These programs reflect the company's commitment to exploring multiple avenues for immunotherapy. BioInvent has established strategic collaborations with major pharmaceutical companies, including Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells, Transgene for co-developing multi-functional oncolytic viruses, and Merck for the clinical development of BI-1808. These partnerships provide valuable resources and expertise to support the advancement of BioInvent's pipeline. The company operates internationally, with a focus on markets in Sweden, Europe, the United States, and Japan.
What They Do
- Discovers and develops immuno-modulatory antibodies for cancer treatment.
- Focuses on therapies that harness the body's immune system to fight cancer.
- Develops BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors.
- Develops antibodies targeting tumor-associated myeloid cells.
- Develops antibodies targeting cancer-associated regulatory T cells.
- Develops BT-001 for solid tumors.
- Develops BI-1808 and BI-1910, anti-TNFR2 antibodies, for solid tumors and cutaneous T-cell lymphoma.
Business Model
- Develops and patents novel immuno-oncology therapies.
- Out-licenses or co-develops drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments, royalties, and supply agreements.
- Focuses on early-stage research and clinical development, partnering for late-stage commercialization.
Industry Context
BioInvent operates within the highly competitive and rapidly evolving biotechnology industry, specifically in the immuno-oncology segment. This segment focuses on developing therapies that harness the body's immune system to fight cancer. The market is characterized by intense research and development activity, with numerous companies vying to develop innovative treatments. Key trends include the increasing use of combination therapies, the development of personalized medicine approaches, and the exploration of novel targets and mechanisms of action. BioInvent's focus on immuno-modulatory antibodies positions it within this dynamic landscape, with the potential to capture a share of the growing market for cancer immunotherapies. Competitors include companies like AVCTF, CLVLY, CYDY, GSGTF, and HLOSF, each pursuing different approaches to cancer treatment.
Key Customers
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients suffering from various types of cancer, particularly non-Hodgkin lymphoma and solid tumors.
- Healthcare providers who prescribe and administer cancer therapies.
- Research institutions and academic centers involved in cancer research.
Financials
Chart & Info
BioInvent International AB (publ) (BOVNF) stock price: Price data unavailable
Latest News
No recent news available for BOVNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BOVNF.
Price Targets
Wall Street price target analysis for BOVNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BOVNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Martin Welschof
CEO
Martin Welschof serves as the CEO of BioInvent International AB. His background includes extensive experience in the biotechnology and pharmaceutical industries. Before joining BioInvent, he held leadership positions at several biotech companies, focusing on drug development and commercialization. His expertise spans across various therapeutic areas, including oncology and immunology. He has a strong track record in strategic planning, business development, and fundraising.
Track Record: Under Martin Welschof's leadership, BioInvent has advanced its pipeline of immuno-oncology assets, including BI-1206, through clinical development. He has also secured strategic collaborations with Pfizer and Merck, providing valuable resources and validation for the company's technology. His focus has been on driving innovation and building a sustainable business model. He manages 114 employees.
BOVNF OTC Market Information
The OTC Other tier, where BioInvent International AB (BOVNF) trades, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Investing in OTC Other stocks carries higher risk due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BOVNF.
- Low trading volume and wide bid-ask spreads can lead to price volatility and execution challenges.
- Lack of regulatory oversight increases the potential for fraud and manipulation.
- The company may not meet minimum listing requirements, indicating potential financial or operational issues.
- OTC Other stocks are generally considered more speculative and carry a higher risk of loss.
- Verify the company's financial statements and disclosures, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Confirm the company's registration and compliance with regulatory requirements.
- Strategic collaborations with reputable pharmaceutical companies like Pfizer and Merck.
- Clinical-stage development of immuno-oncology assets.
- Strong intellectual property portfolio.
- Experienced management team with expertise in drug development.
- Company incorporated in 1996, indicating a long operating history.
What Investors Ask About BioInvent International AB (publ) (BOVNF)
What does BioInvent International AB (publ) do?
BioInvent International AB (publ) is a clinical-stage biotechnology company focused on discovering and developing immuno-modulatory antibodies for cancer treatment. The company's lead drug candidate, BI-1206, is being developed for the treatment of non-Hodgkin lymphoma and solid tumors. BioInvent also has a pipeline of other immuno-oncology assets targeting various aspects of the tumor microenvironment. The company collaborates with major pharmaceutical companies like Pfizer and Merck to advance its drug development programs, aiming to create innovative cancer therapies.
What do analysts say about BOVNF stock?
As of March 18, 2026, there is no readily available analyst consensus on BOVNF stock due to its OTC listing and limited coverage. Key valuation metrics such as P/E ratio (-4.51) and profit margin (-147.0%) reflect the company's current stage of development and investment in research and development. Growth considerations include the potential success of BI-1206 and other pipeline assets, as well as the company's ability to secure additional funding and partnerships. Investors should conduct their own due diligence and consider the risks associated with investing in a clinical-stage biotechnology company.
What are the main risks for BOVNF?
The main risks for BioInvent International AB (publ) include the uncertainty of clinical trial outcomes, competition from other biotechnology and pharmaceutical companies, and regulatory hurdles in drug approval. As a clinical-stage company, BioInvent is heavily reliant on the success of its drug candidates in clinical trials. Failure to achieve positive results or delays in the development process could significantly impact the company's value. Additionally, the company faces competition from larger and more established players in the immuno-oncology market. Securing regulatory approvals and navigating the complex healthcare landscape also present significant challenges.
What are the key factors to evaluate for BOVNF?
BioInvent International AB (publ) (BOVNF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Innovative immuno-oncology pipeline with novel drug candidates.. Primary risk to monitor: Potential: Clinical trial failures and setbacks in drug development.. This is not financial advice.
How frequently does BOVNF data refresh on this page?
BOVNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BOVNF's recent stock price performance?
Recent price movement in BioInvent International AB (publ) (BOVNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative immuno-oncology pipeline with novel drug candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BOVNF overvalued or undervalued right now?
Determining whether BioInvent International AB (publ) (BOVNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BOVNF?
Before investing in BioInvent International AB (publ) (BOVNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited and less reliable than exchange-listed data.
- Analyst consensus may not be available for all OTC stocks.